Matches in Wikidata for { <http://www.wikidata.org/entity/Q82847589> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q82847589 description "2012 թվականին հրատարակված գիտական հոդված" @default.
- Q82847589 description "article scientifique publié en 2012" @default.
- Q82847589 description "artikull shkencor i botuar më 01 janar 2012" @default.
- Q82847589 description "artículu científicu espublizáu en xineru de 2012" @default.
- Q82847589 description "scientific article published on 01 January 2012" @default.
- Q82847589 description "wetenschappelijk artikel" @default.
- Q82847589 description "наукова стаття, опублікована в січні 2012" @default.
- Q82847589 description "научна статия" @default.
- Q82847589 name "Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer" @default.
- Q82847589 name "Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer" @default.
- Q82847589 name "Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer" @default.
- Q82847589 type Item @default.
- Q82847589 label "Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer" @default.
- Q82847589 label "Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer" @default.
- Q82847589 label "Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer" @default.
- Q82847589 prefLabel "Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer" @default.
- Q82847589 prefLabel "Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer" @default.
- Q82847589 prefLabel "Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer" @default.
- Q82847589 P1433 Q82847589-E2E6226A-7DF8-4FC6-815A-36EFBFBC43A3 @default.
- Q82847589 P1476 Q82847589-E1127B74-36AB-4600-A35B-CFDB6987D864 @default.
- Q82847589 P2093 Q82847589-5708F6B3-B30C-4E0B-A790-332646FF10F1 @default.
- Q82847589 P2093 Q82847589-EADD9D87-CEF5-4BC1-B3EB-DF93A17266B5 @default.
- Q82847589 P304 Q82847589-885420E1-140B-4918-94E8-1D85374847E5 @default.
- Q82847589 P31 Q82847589-19373FA1-31A0-4230-A366-868A7C6C8705 @default.
- Q82847589 P31 Q82847589-a3df9e90-0b70-42a9-ac1f-601524e0fea4 @default.
- Q82847589 P356 Q82847589-80F4F556-A942-4F19-8B79-7A1B1E9ADFF7 @default.
- Q82847589 P433 Q82847589-E166769B-EB68-4212-8837-6093B05C3E58 @default.
- Q82847589 P478 Q82847589-DEFE4A44-B3F9-475E-BB8D-EADBAFF8D7D2 @default.
- Q82847589 P577 Q82847589-D4366055-527B-4A2F-8788-2D80F0223FB4 @default.
- Q82847589 P698 Q82847589-BBB4C470-D06F-4E55-9578-377B9FFE17F1 @default.
- Q82847589 P921 Q82847589-E9EFCF9B-7872-4E91-ACF0-6162B793BAAE @default.
- Q82847589 P921 Q82847589-FF8F1B3B-C681-4F0F-BB84-A60C9C8EF8A6 @default.
- Q82847589 P356 ERA.11.196 @default.
- Q82847589 P698 22149426 @default.
- Q82847589 P1433 Q2999044 @default.
- Q82847589 P1476 "Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer" @default.
- Q82847589 P2093 "Diego J Bedoya" @default.
- Q82847589 P2093 "Nicholas Mitsiades" @default.
- Q82847589 P304 "1-3" @default.
- Q82847589 P31 Q13442814 @default.
- Q82847589 P31 Q871232 @default.
- Q82847589 P356 "10.1586/ERA.11.196" @default.
- Q82847589 P433 "1" @default.
- Q82847589 P478 "12" @default.
- Q82847589 P577 "2012-01-01T00:00:00Z" @default.
- Q82847589 P698 "22149426" @default.
- Q82847589 P921 Q181257 @default.
- Q82847589 P921 Q27888393 @default.